Pharmacotherapy for personality disorders

Psychiatry and Clinical Neurosciences

Volumn 52, Issue 1, 1998, Pages 13-19

  Hori, Akira ^a  

^a National Center of Neurology and Psychiatry   (Japan)

Author keywords

Antipsychotic drug; Carbamazepine; Double blind placebo controlled trial; Lithium; Monoamine oxidase inhibitor; Personality disorder; Pharmacotherapy

Indexed keywords

ALPRAZOLAM; CARBAMAZEPINE; DOSULEPIN; IMIPRAMINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OXAZEPAM;

AGGRESSION; BORDERLINE STATE; COMORBIDITY; DEPRESSION; DRUG INDICATION; DRUG RESPONSE; HUMAN; HYSTERIA; PERSONALITY DISORDER; REVIEW; SOCIAL PHOBIA; SUICIDAL BEHAVIOR;

EID: 0031957998     PISSN: 13231316     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1819.1998.tb00967.x     Document Type: Review

References (27)

1. de Girolamo G, Reich JH. Personality Disorders. World Health Organization, Geneva, 1993.
2. Tyrer P, Casey P, Ferguson B. Personality disorder in perspective. In: Tyrer P & Stein G (eds). Personality Disorder Reviewed. GASKEL, London, 1993.
3. Gunderson JG. Pharmacotherapy for patients with borderline personality disorder. Arch. Gen. Psychiatry 1986; 43: 698-700.
4. Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, Hammer RM, Friedel RO. Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch. Gen. Psychiatry 1986; 43: 680-686.
5. Soloff PH, George A, Nathan RS, Schulz PM, Ulrich RF, Perel JM. Progress in pharmacotherapy of borderline disorders: A double-blind study of amitriptyline, haloperidol, and placebo, Arch. Gen. Psychiatry 1986; 43: 691-697.
6. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch. Gen. Psychiatry 1988; 45: 111-119.
7. Dolan B, Coid J. Psychopathic and Antisocial Personality Disorders: Treatment and Research Issues. GASKEL, London, 1993.
8. Barnes RJ. Mesoridazine (Serentil) in personality disorders - A controlled trial in adolescent patients. Dis. Nerv. Syst. 1997; 38: 258-264.
9. Soloff PH, George A, Nathan S et al. Amitriptyline versus haloperidol in borderlines: Final outcomes and predictors of response. J. Clin. Psychopharmacol. 1989; 9: 238-246.
10. Soloff PH, Cornelius J, George A, Nathan S, Perel JM, Ulrich RF. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch. Gen. Psychiatry 1993; 50: 377-385.
11. Montgomery SA, Montgomery D. Pharmacological prevention of suicidal behavior. J. Affect. Disord. 1982; 4: 291-298.
12. Sheard MH. Effect of lithium on human aggression. Nature 1971; 230: 113-114.
13. Sheard MH, Marini JL, Bridges CI, Wagner E. The effect of lithium on impulsive aggressive behavior in man. Am. J. Psychiatry 1976; 133: 1409-1413.
14. Rifkin A, Quitkin F, Carrilo C, Blumberg AG, Klein DF, Oaks G. Lithium in emotionally unstable character disorder. Arch. Gen. Psychiatry 1972; 27: 519-523.
15. Gardner DL, Cowdry RW. Positive effects of carbamazepine on behavioral dyscontrol in borderline personality disorder. Am. J. Psychiatry 1986; 143: 519-522.
16. Soloff PH, George A, Nathan RS, Schulz PM, Perel JM. Paradoxical effects of amitriptyline on borderline patients. Am. J. Psychiatry 1986; 143: 1603-1605.
17. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd edn. APA, Washington DC, 1980.
18. Tracie Shera M, Widiger TA, Klein MH. Comorbidity of personality disorders and depression: Implication for treatment. J. Consult. Clin. Psychology 1992; 60: 857-868.
19. Liebowitz MR, Quitkin FM, Stewart JW et al. Antidepressant specificity in atypical depression. Arch. Gen. Psychiatry 1988; 45: 129-137.
20. Parsons B, Quitkin FM, McGrath PJ et al. Phenelzine, imipramine, and placebo in borderline patients meeting criteria for atypical depression. Psychopharmacol. Bull. 1989; 25: 524-534.
21. Tyrer P, Seivewright N, Ferguson B, Murphy S, Johnson L. The Nottingham study of neurotic disorder: Effect of personality status on response to drug treatment, cognitive therapy and self-help over two years. Br. J. Psychiatry 1993; 162: 219-226.
22. Baer L, Jenike MA, Black DW, Treece C, Rosenfeld R, Greist J. Effect of Axis II diagnosis on treatment outcome with clomipramine in 55 patients with obsessive-compulsive disorder. Arch. Gen. Psychiatry 1992; 49: 862-866.
23. Fahlen T. Personality traits in social phobia, II: Changes during drug treatment. J. Clin. Psychiatry 1995; 56: 569-573.
24. Tyrer P. Personality Disorders: Diagnosis, Management and Course. Wright, London, 1988.
25. Stein G. Drug treatment of the personality disorders. Br. J. Psychiatry 1992; 161: 167-184.
26. Lion JR. Benzodiazepines in the treatment of aggressive patients. J. Clin. Psychiatry 1979; 40: 70-71.
27. Gardner DL, Cowdry RW. Alprazolam-induced dyscontrol in borderline personality disorder. Am. J. Psychiatry 1985; 142: 98-100.